Mutant glucocerebrosidase impairs α-synuclein degradation by blockade of chaperone-mediated autophagy
Sheng‐Han Kuo, Inmaculada Tasset, Melody M. Cheng, Antonio Díaz, Ming‐Kai Pan, Ori J. Lieberman, Samantha J. Hutten, Roy N. Alcalay, Sangjun Kim, Pilar Ximénez‐Embún, Li Fan, Donghoon Kim, Han Seok Ko, Talene A. Yacoubian, Ellen Kanter, Ling Liu, Guomei Tang, Javier Muñoz, S. Pablo Sardi, Aiqun Li, Li Gan, Ana María Cuervo, David Sulzer
Abstract
The most common genetic risk factors for Parkinson’s disease (PD) are a set of heterozygous mutant (MT) alleles of the GBA1 gene that encodes β-glucocerebrosidase (GCase), an enzyme normally trafficked through the ER/Golgi apparatus to the lysosomal lumen. We found that half of the GCase in lysosomes from postmortem human GBA-PD brains was present on the lysosomal surface and that this mislocalization depends on a pentapeptide motif in GCase used to target cytosolic protein for degradation by chaperone-mediated autophagy (CMA). MT GCase at the lysosomal surface inhibits CMA, causing accumulation of CMA substrates including α-synuclein. Single-cell transcriptional analysis and proteomics of brains from GBA-PD patients confirmed reduced CMA activity and proteome changes comparable to those in CMA-deficient mouse brain. Loss of the MT GCase CMA motif rescued primary substantia nigra dopaminergic neurons from MT GCase–induced neuronal death. We conclude that MT GBA1 alleles block CMA function and produce α-synuclein accumulation.